Target Identification & Drug Research and Development

We aim to accelerate the research process of complex disease mechanisms and fundamentally boost the efficiency of life science research and development.

RESEARCH FOCUS

We are currently focused on several disease areas, including but not limited to immuno-oncology (e.g., liver cancer, lung cancer, and gastrointestinal tumors), fibrosis (e.g., liver fibrosis, pulmonary fibrosis, and renal fibrosis), autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, and systemic lupus erythematosus), and aging-associated changes of the immune system.

Drug Pipeline Under Development

Focus Area Project No. Indication

Evaluation

Discovery

PCC Stage

Clinical Stage

Tumor Immunity BP-001 Pan-solid tumors
BP-011 Pan-solid tumors such as gastric cancer/liver cancer
BP-101 Gastric cancer
BP-103 Liver fibrosis/early liver cancer
Autoimmune diseases BP-002 Autoimmune diseases
BP-012 Inflammatory bowel disease
BP-102 Ankylosing spondylitis
Aging-related disease BP-104 Undisclosed

Projects in Research

Focusing on immune related diseases and problems, we have been actively initiating clinical based scientific research cohort projects while using high-dimensional multi-omics engines and high-throughput functional verification platforms to obtain high quality biological big data to transform high value problems.

Focus Area Disease Focus Study Evaluation Recruiting & Omics Analyis Data Mining & Validation Publication/Conclusion
Tumor immunity Tumor immunity The relationship between tumor microenvironment (cell subsets, status, regulatory factors, degree of fibrosis) and immune escape and immune activation
Liver cancer The influence of tumor microenvironment on the prognosis of patients with early and late liver cancer
Lung cancer A case-control study on the regulatory mechanism of local infiltration of lung adenocarcinoma
20%
Gastric cancer Explore the mechanism of HP-induced gastric mucosal disease
10%
Ovarian cancer An exploratory study of a single-agent neoadjuvant treatment of advanced epithelial ovarian cancer
20%
Autoimmune diseases AS&IBD Early diagnosis of ankylosing spondylitis and inflammatory bowel disease and biomarker mining for patient classification
IBD A case-control study on the response mechanism of patients with Crohn's disease to a drug treatment
10%